Thrombosis and COVID-19 vaccines

Article Sidebar

PDF PDF (Português (Brasil))
Published: Jun 20, 2021
DOI: https://doi.org/10.21876/rcshci.v11i2.1165
Keywords:
COVID-19, vaccines

Main Article Content

Melissa Andreia de Moraes Silva
Itajubá Clinics Hospital, Faculty of Medicine of Itajubá, Brazilian Society of Angiology and Vascular Surgery
https://orcid.org/0000-0001-8773-3095
Mateus Alves Borges Cristino
Brazilian Society of Angiology and Vascular Surgery
https://orcid.org/0000-0001-9487-9770
Ricardo Jayme Procópio
Hospital das Clínicas da UFMG, Sociedade Brasileira de Angiologia e Cirurgia Vascular
https://orcid.org/0000-0003-0094-8945

Abstract

Vaccines against COVID-19 from Moderna Biotech Spain, SL (COVID-19 Vaccine Moderna – mRNA technology), AstraZeneca (Oxford/Astrazeneca Vaccine - ChAdOx1 - adenovirus vector technology) and Janssen-Cilag International NV (COVID-19 Vaccine) Janssen - Ad.26.COV2.S - adenovirus vector technology) used in Europe, the United States and Brazil has presented severe thrombotic adverse reactions. The recorded thrombosis occurred in unusual sites, such as the sagittal venous sinus.

Article Details

How to Cite
1.
de Moraes Silva MA, Cristino MAB, Procópio RJ. Thrombosis and COVID-19 vaccines. Health Sci J [Internet]. 2021Jun.20 [cited 2024Apr.25];11(2):1-. Available from: https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1165
Issue
Vol 11 No 2 (2021): April to June 2021
Section
EDITORIAL
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors maintain copyright and grant the Health Sciences Journal the right to first publication. From 2024, the publications wiil be licensed under Attribution 4.0 International , allowing their sharing, recognizing the authorship and initial publication in this journal.

Authors are authorized to assume additional contracts separately for the non-exclusive distribution of the version of the work published in this journal (e.g., publishing in an institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.

Authors are encouraged to publish and distribute their work online (e.g., in institutional repositories or on their personal page) at any point after the editorial process.

Also, the AUTHOR is informed and consents that the Health Sciences Journal can incorporate his article into existing or future scientific databases and indexers, under the conditions defined by the latter at all times, which will involve, at least, the possibility that the holders of these databases can perform the following actions on the article.

Author Biographies

Melissa Andreia de Moraes Silva, Itajubá Clinics Hospital, Faculty of Medicine of Itajubá, Brazilian Society of Angiology and Vascular Surgery

Doctor and Master in Sciences from the Federal University of São Paulo (Unifesp/EPM). Vascular Surgeon and Vascular Ultrasonographer by CNRM/MS and SBACV/AMB. Professor at the Faculty of Medicine of Itajubá. Effective Member of the Brazilian Society of Angiology and Vascular Surgery.

Mateus Alves Borges Cristino, Brazilian Society of Angiology and Vascular Surgery

Vascular Surgeon by CNRM/MS and SBACV/AMB. Vascular Ultrasonographer by SBACV/AMB. Effective Member of SBACV. Specialist in Angioradiology and Endovascular Surgery by SBACV and CBR. Member of the Society for Vascular Surgery (SVS). Effective Member of SBACV.

Ricardo Jayme Procópio, Hospital das Clínicas da UFMG, Sociedade Brasileira de Angiologia e Cirurgia Vascular

Medical residency in vascular surgery at HSPE-SP and in Angioradiology and Endovascular Surgery at Instituto Dante Pazzanese de Cardiologia-SP. Coordinator of the specialization in endovascular surgery at Hospital das Clínicas of the Universidade Federal de Minas Gerais (UFMG). Member of the Brazilian Society of Angiology and Vascular Surgery.

References

Franchini M, Liumbruno GM, Pezzo M. COVID-19 Vaccine-associated Immune Thrombosis and Thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol. 2021. https://doi.org/10.1111/ejh.13665 Epub PMid:33987882
Mahase E. COVID-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency. BMJ. 2021;372:n774. https://doi.org/10.1136/bmj.n774 PMid:33741638
Ovadia D, Univadis (Website). No ad Astra Zeneca per i più giovani, sì a vaccini diversi combinati [article in Italian]. 2021 Jun 10 [cited 2021 Jun 20]. Avaiable from: https://bit.ly/3j91hVV
Hunter PR. Thrombosis after COVID-19 vaccination. BMJ. 2021;373:n958. https://doi.org/10.1136/bmj.n958 PMid:33853865
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384(22):2092-101. https://doi.org/10.1056/NEJMoa2104840 PMid:33835769 PMCid:PMC8095372
United Kingdom, Public Health England. Guidance: covid-19 vaccination and blood clotting [Internet]. 2021 [updated 2021 May 21]. Avaiable from: https://bit.ly/3g78vaY
Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890. https://doi.org/10.1136/bmj.b2890 PMid:19679613 PMCid:PMC2726928
Pai M, Schull M, Razak F, et al. Vaccine-induced prothrombotic immune thrombocytopenia VIPIT following AstraZeneca COVID-19 vaccination: interim guidance for healthcare professionals in emergency department and inpatient settings. Science Briefs of the Ontario COVID-19 Science Advisory Table. 2021;1(21). https://doi.org/10.47326/ocsat.2021.02.21.1.0
Brasil, Ministério da Saúde, Agência Nacional de Vigilância Sanitária. Comunicado: suspensão da vacina da AstraZeneca para gestantes [Internet]. [published 2021 May 11; cited 2021 jun 9]. Avaiable from: https://bit.ly/3pCnmgx